CharlesAlexanderLeathIIIMD

PubMed

• 278 citations
  Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
  Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian
  Journal of the National Comprehensive Cancer Network. 2020-03-01
• 61 citations
  Validation of referral guidelines for women with pelvic masses.
  Samuel S. Im, Alan N. Gordon, Barbara M. Buttin, Charles A. Leath, Bobbie S. Gostout
  Obstetrics and Gynecology. 2005-01-01
• 35 citations
  Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
  Warner K. Huh, William E. Brady, Paula M. Fracasso, Don S. Dizon, Matthew A. Powell
  Gynecologic Oncology. 2020-09-01

Journal Articles

• The evolution of and evidence for opportunistic salpingectomy  
  Dilley SE, Straughn JM Jr., Leath CA III, Obstet Gynecol, 1/1/2017
• Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic ...  
  Phippen NT, Secord AA, Wolf S, Samsa G, Davidson B, Abernethy AP, Cella D, Havrilesky LJ, Burger RA, Monk BJ, Leath CA III, Gynecol Oncol, 1/1/2017
• Malignant Brenner tumor associated with a germline BRCA2 mutation  
  Toboni MD, Smith HJ, Dilley SE, Novak L, Leath CA, Gynecol Oncol Rep, 1/1/2017
• Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients?  
  Daily LR, Boone JD, Machemehl HC, Thomas ED, McGwin G Jr., Straughn JM Jr., Leath CA III, Int J Gynecol Cancer, 1/1/2017
• A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF ...  
  Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Thigpen JT, Lieberman R, Zuna RE, Leath CA III, Spirtos NM, Byron J, Thaker PH, Lele S, Albe..., Gynecol Oncol, 1/1/2017
• Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – a multi-institutional cohort  
  Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM, Gunderson CC, Moore KN, Erickson BK, Leath CA III, Diaz ES, Cohen J, Walsh C, Gynecol Oncol, 1/1/2017
• Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GO...  
  Miller C, Chappell N, Sledge C, Leath CA III, Phippen N, Havrilesky L, Barnett JC, Gynecol Oncol, 1/1/2017
• Improved outcomes with dose-dense paclitaxelbased neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma  
  Becker DA, Thomas ED, Gilbert AL, Boone JD, Straughn JM Jr., Huh WK, Bevis KS, Leath CA III, Alvarez RD, Gynecol Oncol, 1/1/2016
• Staging lymphadenectomy in patients with clear cell carcinoma of the ovary  
  Mueller JJ, Holzapfel M, Han C, Santos K, Gunderson C, Moore K, Erickson B, Leath CA III, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman D..., Int J Gynecol Cancer, 1/1/2016
• Drawing the line in risk reducing gynecologic surgery in women with a BRCA mutation  
  Leath CA III, Huh WK, Alvarez RD, JAMA Oncol, 1/1/2016
• Distance from a comprehensive cancer center: A proxy for poor cervical cancer outcomes?  
  Barrington DA, Dilley S, Landers EE, Thomas ED, Boone JD, Straughn JM Jr., McGwin G, Leath CA III, Gynecol Oncol, 1/1/2016
• The impact of diabetes on gynecologic cancer: Current status and future directions  
  Lees B, Leath CA III, Curr Obstet Gynecol Rep, 1/1/2015
• PARP inhibitor therapy for patients with platinum-sensitive recurrent ovarian cancer: a costeffectiveness analysis  
  Smith HJ, Walters CL, Arend RC, Leath CA III, Straughn JM, Gynecol Oncol, 1/1/2015
• Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis  
  Previs RA, Leath CA III, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA, Gynecol Oncol, 1/1/2015
• Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project  
  Shah MS, Leath CA III, Daily LR, McGwin G Jr., Estes JM, Alvarez RD, Straughn JM Jr, Int J Gynecol Cancer, 1/1/2015
• Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?  
  Phippen NT, Leath CA III, Havrilesky L, Barnett JC, Gynecol Oncol, 1/1/2015
• Black race independently predicts worse survival in uterine carcinosarcoma  
  Erickson BK, Doo DW, Zhang B, Huh WK, Leath CA III, Gynecol Oncol, 1/1/2014
• Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma  
  Doo DW, Erickson BK, Arend RC, Conner MG, Huh WK, Leath CA III, Gynecol Oncol, 1/1/2014
• Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center  
  Erickson BK, Martin JM, Shah MS, Straughn JM Jr., Leath CA III, Gynecol Oncol, 1/1/2014
• Combination therapy with paclitaxel, carboplatin and megesterol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study  
  Bevis KS, Kilgore LC, Alvarez RD, Straughn JM Jr., Leath CA III, J Reprod Med, 1/1/2014
• Diabetes mellitus and ovarian cancer: More complex than just increasing risk  
  Shah MM, Erickson BK, Matin, T, McGwin J Jr., Martin YM, Daily LB, Pasko D, Haygood CW, Fauci, JM, Leath CA III, Gynecol Oncol, 1/1/2014
• Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer  
  Erickson BK, Devine LM, Leath CA III, Straughn JM Jr, Int J Gynecol Cancer, 1/1/2014
• A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer  
  Krivak TC, Lele S, Richard S, Alvarez Secord A, Leath CA III, Brower SL, Tian C, Moore RG, Am J Obstet Gynecol, 1/1/2014
• Growing teratoma syndrome: Brief communication and algorithm for management  
  Byrd K, Stany MP, Herbold NC, Leath CA III, Hamilton CA, Aut N Z J Obstet Gynaecol, 1/1/2013
• Are supportive-care based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?  
  Phippen NT, Leath CA III, Miller CR, Lowery WJ, Havrilesky LJ, Barnett JC, Gynecol Oncol, 1/1/2013
• Join now to see all

Abstracts/Posters

• The cost-effectiveness of salpingectomy versus standard tubal ligation at the time of cesarean delivery
  Subramaniam A, Blanchard CT, Erickson BK, Szychowski J, Leath CA III, Biggio J, Huh WK, 38th Annual Meeting of Society of Maternal Fetal Medicine, Dallas, Texas, 1/1/2018
• Impact of enhanced recovery after surgery (ERAS) protocol on the gastrointestinal tract in gynecologic oncology patients undergoing laparotomy
  Boitano T, Smith HJ, Rushton T, Johnston MC, Leath CA III, Straughn JM Jr, 23rd Winter meeting of the Society of Gynecologic Oncology, Aspen, Colorado, 1/1/2018
• Analysis of clinical cancer gene panels by next generation sequencing in tumor and circulating cell-free DNA samples in recurrent ovarian cancer patients
  Londono AI, Farrukh N, Smith MK, Tawfik C, Alvarez RD, Huh WK, Bevis KS, Leath CA, Straughn JM, Yang SH, Harada S, Kim KH, Arend RC, 2017 AACR Precision Medicine Series, San Diego, CA, 1/1/2017
• A multi-institutional analysis for surgery and chemotherapy for Stage IB uterine carcinosarcoma
  Vandersluis A, Wade KS, Ding K, Backes F, Cosgrove C, ElNaggar A, Richardson D, Liu C, Roane B, Erickson B, Leath CA III, Moore KN, Gunderson CC, 22nd Annual Society of Gynecologic Oncology Winter Meeting, Breckinridge, CO, 1/1/2017
• Phase I study of the safety of activity of intraperitoneal IL-12 plasmid administered in combination with standard neoadjuvant chemotherapy in patients with newly diag...
  Thaker P, Bradley W, Leath CA III, Moore K, Borys N, Anwer K, Musso L, Alvarez RD, ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, 1/1/2017
• Immunologic changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemotherapy in patients with newly...
  Anwer K, Bshara W, Lugade A, Omillian A, Matsuzaki J, Thaker P, Bradley W, Leath CA III, Moore K, Borys N, Odunsi, ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, 1/1/2017
• Validation of an assessment tool for OSCE “Fill in the Gap” Milestones on Pelvic Mass
  Shields A, Hoffman S, Rauk P, Leath CA III, Ricciotti H, APGO/CREOG Annual Meeting, Orlando, FL, 1/1/2017
• Using value-based tools to determine the value of bevacizumab in cervical and ovarian cancer
  Smith HJ, Cooper K, Leath CA III, Rocque BG, Bevis KS, Huh WK, Straughn JM Jr, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• A multi-institutional analysis of patterns of recurrence and survival with clear cell carcinoma of the ovary
  Dockery LE, Duggan K, Vesely S, Leath CA III, Dilley SE, Tseng JH, Mueller JJ, Ding K, Gunderson CC, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Correlation between frozen section and final pathology in women with suspected gynecologic malignancies
  Thomas ED, Hoepfner L, Schointuch M, Miller K, Straughn JM Jr., Leath CA III, Conner MG, Novak L, Boone JD, Kim KH, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Demographic and geographic factors associated with advanced cervical cancer in a rural state
  Powell TC, Dilley SE, Bae S, Straughn JM Jr., Kim KH, Leath CA III, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Quantitative and qualitative evaluations of pediatrician attitudes and barriers to HPV vaccination
  Dilley SE, McGuire AA, Straughn JM Jr., Leath CA III, Scarinci IC, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Using DrugAbacus to determine the value of PD-1 inhibitors in ovarian cancer: How much should they cost?
  Cooper K, Smith HJ, Leath CA III, Arend RC, Kim, KH, Straughn JM Jr, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Evaluation of major postoperative complications in gynecologic oncology patients undergoing bowel surgery: A quality improvement project
  Smith HJ, Boone JD, Bevis KS, Leath CA III, Huh WK, Straughn JM Jr, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Predictors of unplanned reoperation for ovarian cancer patients from the National Surgical Quality Improvement Program database
  Toboni MD, Bae S, Straughn JM Jr., Leath CA III, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Impact of consistent intraoperative assessment on predicting tumor size, myometrial invasion, and cervical involvement: Results from an observational cohort
  Smith BQ, Boone JD, Thomas ET, Turner TB, McGwin G, Stisher AM, Leath CA III, Huh WK, 48th Annual Meeting of the Society of Gynecologic Oncology, Washington, DC, 1/1/2017
• Analysis of gene expression patterns and metabolomics correlated to obesity, diabetes, and outcomes in patients with epithelial ovarian cancer
  Montgomery AA, Londono AI, Craig ER, Tawfik C, Smith HJ, Leath CA, Katre AA, Cooper SJ, Arend RC, 108th AACR Annual Meeting, Washington, DC, 1/1/2017
• Evaluation of African American women at high risk for ovarian cancer in the southeast
  Barrington DA, Champion ML, Farmer MB, Haygood CW, Boitano TK, Leath CA III, 65th Annual Meeting of American Congress of Obstetricians and Gynecologists, San Diego, CA, 1/1/2017
• Racial, geographic, and socioeconomic risk factors for development of advanced stage cervical cancer
  Dilley SE, Powell TC, Bae S, Straughn JM Jr., Leath CA, Kim KH, 65th Annual Meeting of American Congress of Obstetricians and Gynecologists, San Diego, CA, 1/1/2017
• Evaluation of the adequacy of surgical staging and operative morbidity in patients undergoing surgery for stage I ovarian and fallopian tube carcinoma in a military tr...
  Sawtelle A, Miller C, Leath CA III, Dengler, K, 65th Annual Meeting of American Congress of Obstetricians and Gynecologists, San Diego, CA, 1/1/2017
• Phase 1 study of the safety and activity of formulated IL-12 plasmid administered intraperitoneallly in combination with neoadjuvant chemotherapy in patients with newl...
  Thaker PH, Bradley WH, Leath CA III, Gunderson CC, Borys N, Anwer K, Musso L, Alvarez RD, ASCO Annual Meeting, Chicago, IL, 1/1/2017
• High-intermediate risk endometrial cancer: Can gene expression predict recurrence?
  Tawfik C, Kim B, Londono A, Katre AA, Della Manna DL, Huh WK, Yang E, Bevis KS, Straughn JM, Leath CA, Arend RC, ASCO Annual Meeting, Chicago, IL, 1/1/2017
• Racial disparities in hereditary gynecologic cancer risk assessment: what and why?
  Barrington D, Batra D, McGwin G Jr., Turner TB, Farmer M, Brown AM, Straughn JM Jr., Leath CA III, 19th Annual UAB Comprehensive Cancer Center Retreat, Birmingham, AL, 1/1/2017
• Baseline serum protein levels associated with survival in axalimogene filolisbac (AXAL)-treated metastatic cervical cancer patients: The GOG/NGR 0265 Trial
  Hayes SM, Petit RG, Balli D, Hong Q, Huh W, Brady WE, Dizon D, Powell MA, Leath CA III, Landrum LM, Tanner E, Higgins R, Ueda S, McHale M, Aghajanian C, Monk BJ, 20th Annual Meeting of the European Society of Gynecological Oncology, Vienna, Austria, 1/1/2017
• Is intraoperative gross evaluation of the uterus in patients with complex atypical hyperplasia and endometrial adenocarcinoma reliable?
  Smith B, Boone J, Thomas E, Turner T, McGwin G, Leath CA, Huh WK, 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 1/1/2016
• Join now to see all

Lectures

• A randomized controlled trial of salpingectomy versus standard tubal ligation at the time of cesarean delivery 
  Dallas, Texas - 1/1/2018
• Demographic and geographic factors associated with advanced cervical cancer in a rural state 
  Tuscaloosa, AL - 1/1/2017
• Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma 
  Washington, DC - 1/1/2017
• A prospective phase II trial of the listeria-based human papillomavirus immunotherapy axalimogene filolisbac in second- and third-line metastatic cervical cancer: An N... 
  Washington, DC - 1/1/2017
• Utilization of the university HealthSystem Consortium database and a departmental quality committee to evaluate adverse outcomes in a large inpatient gynecologic oncol... 
  Chicago, IL - 1/1/2015
• PARP inhibitors as maintenance therapy for platinum-sensitive ovarian cancer: can we afford it? 
  Chicago, IL - 1/1/2015
• Association between quality of life and clinical outcomes in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevac... 
  Chicago, IL - 1/1/2015
• Accuracy of colposcopic impression in pregnancy 
  Scottsdale, AZ - 1/1/2014
• Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma 
  Washington, DC - 1/1/2013
• Comparative effectiveness of chemotherapy versus hospice in recurrent cancer of the uterine cervix 
  Las Vegas, NV - 1/1/2012
• Evaluation of surgical outcomes in advanced ovarian cancer in a low volume military treatment facility 
  Las Vegas, NV - 1/1/2012
• Laparoscopic staging of ovarian immature teratomas: A report on 3 cases 
  San Diego, CA - 1/1/2011
• Intra-cycle laboratory surveillance in gynecologic oncology patients receiving combination chemotherapy: Does this practice predict treatment delays? 
  San Diego, CA - 1/1/2011
• Incorporation of the 2009 cervical cancer screening guidelines into clinical practice 
  San Antonio, TX - 1/1/2011
• Pregnancy after endometrial cryoablation and hysteroscopy sterilization 
  San Antonio, TX - 1/1/2010
• Delivery outcomes in active duty military women following military deployment 
  San Antonio, TX - 1/1/2010
• Evaluation of cytotoxic chemotherapy and hormonal therapy for advanced stage/recurrent endometrial carcinoma: Final results of a phase II trial of combination therapy ... 
  San Antonio, TX - 1/1/2010
• Robotic ovarian cancer surgery in an adolescent 
  San Francisco, CA - 1/1/2010
• Initiation of a gynecologic cancer screening clinic: A performance improvement project of initial experience and patient characteristics 
  Honolulu, HI - 1/1/2009
• Hospice enrollment for terminally ill patients with gynecologic malignancies: The impact on outcomes and interventions 
  Honolulu, HI - 1/1/2009
• Comparison of surgical outcomes and complications for clinical stage I endometrial cancer: Laparoscopy versus laparotomy in a military treatment facility 
  Honolulu, HI - 1/1/2009
• A case report of synchronous primary tumors of the uterus and cervix: A call for thorough pre-operative evaluation 
  Louisville, Kentucky - 1/1/2007
• Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary 
  San Diego, CA - 1/1/2007
• Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapy 
  Sonthofen, Germany - 1/1/2006
• Conservative management of post-operative fever 
  West Virginia - 1/1/2006
• Join now to see all

Other

• Evaluation of the Acute Abdomen 
  Campbell AW, Leath CA III, BMJ Point of Care/Epocrates Online
  San Mateo, CA - 1/1/2016
• The new focus on IL-12 in oncology research 
  Thaker P, Leath CA III, Drug Discovery and Development
  http://www.dddmag.com/articles/2016/04/new-focus-il-12-oncology-research
  1/26/2016
• Research is expanding into the use of Interleukin-12 as an anticancer agent 
  Leath CA, Thaker P, Cancer Therapy Advisor
  http://www.cancertherapyadvisor.com/supportive-care/interleukin-12-research-anticancer-treatment-expand-use/article/493853/
  1/3./2016